Status and phase
Conditions
Treatments
About
The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.
Full description
The research aims to answer the question: "Does the addition of a Glucagon-like Peptide-1 (GLP-1) to standard progestin treatment lead to a higher complete response rate compared to historical response rates using progestin alone in young patients with endometrial cancer/atypical hyperplasia who wish to preserve their fertility?".
This is a multicentre single arm open-label phase II clinical trial to assess the complete pathologic response as determined by endometrial sampling after 48 weeks of semaglutide (GLP-1) and progestin therapy in patients with BMI ≥ 27 who have endometrial cancer/atypical hyperplasia and desire fertility preservation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Evidence of myometrial invasion or extra-uterine disease on imaging
High grade or p53 mutated (p53mut) endometrial cancer
Estrogen receptor negative endometrial cancer (positivity defined as moderate/strong staining>10%)
Mismatch repair deficient (MMRd) endometrial cancer
History of other malignancies except if curatively treated with no evidence of disease for >5 years
Previous surgical treatment of obesity
Current use of weight loss medication (no use in last 2 months)
Medical comorbidity with end-organ dysfunction
History of suicide attempts or current suicidal thoughts or behaviours
Currently taking insulin or insulin secretagogue (e.g., sulfonylurea)
Diabetic retinopathy
Gastroparesis or problems with food digestion
History of tachycardia (e.g., sinus tachycardia, supraventricular tachycardia, atrial fibrillation, atrial flutter, or ventricular tachycardia)
Contraindications to pIUD or semaglutide.
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Primary purpose
Allocation
Interventional model
Masking
71 participants in 1 patient group
Loading...
Central trial contact
Vanessa Ballin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal